Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure
Status:
Completed
Trial end date:
2016-06-06
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to test the hypothesis that high-dose spironolactone
will lead to greater proportional reduction in NT-proBNP levels from randomization to 96
hours over standard of care.